Sesquiterpenoid nootkatone and derivatives produced via engineered P450 enzymatic oxidation

Overview

Nootkatone is a naturally occurring sesquiterpenoid valued in flavour and fragrance markets for its characteristic grapefruit aroma. This solution leverages engineered P450 enzyme variants to oxidise natural product precursors, producing nootkatone and a series of novel derivatives under mild, biocatalytic conditions. Beyond its established sensory applications, nootkatone is a known insecticide with a mode of action distinct from conventional chemistries, reducing the likelihood of cross-resistance. Early exploratory testing suggests the engineered derivatives may also exhibit insecticidal efficacy, opening potential new applications in crop protection and pest management.

Technical specifications

• Biocatalytic synthesis: P450 enzyme variants catalyse the oxidation of natural-product-derived precursors to yield nootkatone and derivative compounds.
• Engineered enzyme panel: Multiple P450 variants have been developed and optimised to broaden the accessible derivative chemical space beyond what is achievable through traditional chemical synthesis.
• Natural product origin: Starting materials are derived from natural product feedstocks, supporting a potentially sustainable production pathway.
• Differentiated insecticidal mode of action: Nootkatone acts through a mechanism distinct from existing insecticides, which may help limit the development of resistance in target pest populations.
• Dual market potential: Compounds are positioned for both flavour and fragrance applications and exploratory use as insecticidal active ingredients.

Technology readiness level

The core biotransformation process for producing nootkatone has been established and demonstrated. Engineered P450 variants for derivative production have been developed, and early exploratory tests suggest potential insecticidal efficacy for the derivatives, though further validation data is needed. The technology is at an early-to-mid stage of development, with opportunities for partnership to advance derivative characterisation, efficacy testing, and scale-up.